Celera Genomics Appoints Gerald A. Steiner as Senior Vice President and General Manager, Genomics Services.

Business Editors/Health & Medical Writers

ROCKVILLE, Md.--(BW HealthWire)--June 1, 2000

Celera Genomics (NYSE:CRA), a PE Corporation business, announced today that Gerald A. Steiner has joined Celera as senior vice president and general manager, genomics services.

In this new position, Steiner will lead the genomics services business line, which includes the single nucleotide polymorphisms (SNPs), gene discovery, gene expression analysis, agricultural genomic services, contract services, as well as collaborations with major customers for the application of genetic material.

Steiner comes to Celera from the Monsanto Company and brings with him 18 years of successive and progressive product and business development. Most recently he served as general manager, Europe-Africa agricultural business based in Brussels, Belgium. In this position he led a multi-million dollar agricultural, chemical seed and biotechnology traits business. In previous roles he was instrumental in leading the development and marketing of several important Monsanto products.

Steiner received his MBA in 1992 from Washington University and his BS in 1982 in Agricultural Economics from the University of Wisconsin-Madison.

"We are excited to have Jerry join the Celera team. His diverse experience in global direct marketing makes him ideal to lead Celera in the next phases of our business development which include proteomics and functional genomics," said J. Craig Venter, PhD, Celera's president and chief scientific officer. "We look forward to having Jerry help us build key business collaborations with customers worldwide."

Currently, Celera's information is available through the Internet on a subscription basis to academic and commercial institutions. Users have the ability to view, browse, and analyze data in an integrated way, thus acceleration their understanding of a variety of genomes, including the human, Drosophila, and ultimately the mouse and other agricultural genomes.

PE Corporation comprises two operating groups. The PE Biosystems Group (NYSE:PEB), with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. PE Biosystems is headquartered in Foster City, Calif., and comprises four divisions: Applied Biosystems, PE Informatics, PerSeptive Biosystems, and Tropix. The Celera Genomics Group (NYSE:CRA), headquartered in Rockville, Md., intends to become the definitive source of genomic and related medical information. Information about the Company, including reports and other information filed by the Company with the Securities and Exchange Commission, is available on the worldwide web at www.pecorporation.com or by phoning 800/762-6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "anticipate," "should," "intend," "planned," "estimated," and "potential" among others. These forward-looking statements are based on PE Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics' businesses include but are not limited to (1) operating losses to date; (2) a unique and developing business plan; (3) dependence on the timely completion of the sequencing and assembly of the human genome; (4) uncertainty of revenue growth; (5) unproven use of genomics information to develop products; (6) intense competition in the evolving genomics industry; (7) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (8) heavy reliance on strategic relationship with the PE Biosystems group; (9) potential product liability claims; (10) liabilities related to use of hazardous materials; (11) lengthy sales cycle; (12) dependence on the unique expertise of its scientific and management staff; (13) uncertainty of patent, copyright and intellectual property protection; (14) dependence on computer hardware, software, and internet applications; (15) access to biological materials; (16) legal, ethical and social issues affecting demand for products; (17) disruptions caused by rapid growth of the business; (18) government regulation of its products and services; (19) risks of future acquisitions; and (20) other factors that might be described from time to time in PE Corporation's filings with the Securities and Exchange Commission.

Note to Editors: Celera, Celera Genomics, and PE Biosystems are trademarks of PE Corporation.